Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
Rhea-AI Summary
Editas Medicine, a prominent genome editing company, announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 10:15 AM ET. The presentation will be webcast live on their website, with archived recordings available for 30 days post-event.
Editas focuses on utilizing CRISPR technologies to develop precise genomic medicines aimed at treating serious diseases globally.
Positive
- None.
Negative
- None.
News Market Reaction – EDIT
In the trading session that priced this news, EDIT declined 1.74%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET.
The event will be webcast live and may be accessed on the Editas Medicine website in the Investors section. Archived recordings will be available for approximately 30 days following the event.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor Contact
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media Contact
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com